Where to buy Setmelanotide online? Factory supply best Setmelanotide powder CAS 920014-72-8 Purity 98% from Green Stone.
If you have any questions or suggestions about the use, function, specification character, quotation, pirce and application of Setmelanotide, please contact us! We will give you detailed answers.
Place of Origin China
MOQ 1 kg
Payment Term T/T 100% paid in advance
The info on web just for reference showing,
Pls contact us to ask for more correct details, including Price & COA and so on.
Trade Names: Imcivree
CAS NO.: 920014-72-8
Molecular Formula: C49H68N18O9S2
Molecular Weight: 1117.32
Appearance: White Powder
Solubility: Soluble in Water/DMSO
Mechanism of Action
1. The mechanism of activating MC4R may be different from natural ligands and synthetic agonists;
2. It may play a role by antagonizing the naturally occurring neurotransmitters that inhibit MC4R activation;
3. It can activate specific MC4R mutations that the natural ligand MSH (melanocyte hormone) cannot activate, which may allow it to play a role in the treatment of other types of obesity;
For the treatment of obesity and management of hunger and weight reduction in children and adults with rare obesity aged ≥ 6 years.
Description About Setmelanotide
Setmelanotide is a melanocortin 4 receptor (MC4R) agonist acting on human and rat melanocortin 4 receptors for the treatment of hypothalamic obesity.
Setmelanotide is a first-in-class, oligopeptide MC4R agonist with 20-fold reduced activity at the melanocortin 3 (MC3) and melanocortin 1 (MC1) receptors, developed for the treatment of a rare genetic disorder of obesity. MC4R is part of a key biological pathway that the body independently regulates energy expenditure and appetite. Gene variants may impair the function of the MC4R pathway, which can lead to extreme hunger (hyperappetite) and early-onset severe obesity. Currently, setmelanotide is being developed as a targeted therapy to restore the function of the damaged MC4R pathway, re-establish energy expenditure and appetite control, reduce hunger and reduce body weight in patients with rare genetic diseases of obesity. Currently, there are no drug therapies to treat these rare genetic diseases of obesity.
Setmelanotide, a drug that can genetically help people who have difficulty losing weight, reported the clinical trials of this new drug in the Wall Street Journal on September 7, 2016. Setmelanotide is the first FDA-approved treatment for these genetic conditions.
Get A Free Quote Now!
Just tell us your requirements, we can do more than you can imagine.
E-mail: [email protected](Reply within 1 working day)